The Oncology Business Dynamics modulettes are succinct learning modules focusing in and diving deep on one topic. "Modulettes" is a term we developed to describe these device-compatible, bite-sized learning modules. Check out our library of modulette topics, and view our demo to get a feel for them.
Modulettes are designed to be bite-sized, thus there are of them with each one focusing on a particular topic. But each one still has a Situational Overview, Learning Objectives, and Key Points, and they are annotated and referenced. The modulettes are produced in HTML5, and they are responsive meaning they are easily viewed on desktop, laptop, or tablets/devices.
What’s new in the Oncology Business Dynamics library? We’re glad you asked!
Clinical Trial Phases and Regulatory Approval describes the different phases of clinical trials (1-4) and what's expected in each phase, then segues into the submission process for FDA approval, which includes information on INDs, NDAs, ODAC, and the 4 expedited tracks FDA has for quicker approval of life-threatening drugs.
The Dynamics of Medicare Part D Prescription Drug Plans was created to provide a deeper understanding of Part D drug plans. Topics covered include, what the plans are, what they cover, role of the P&T committee, the donut hole, overview of out-of-pocket costs for 15 specialty tier cancer drugs and payer utilization management.
The Explanation of Oncology Clinical Trial Endpoints includes an explanation of emerging and traditional endpoints used in clinical trials, such as "surrogate" "direct" and "efficacy" endpoints, as well as tumor response rates as defined by RECIST criteria, and the potential advantages and limitations of several types of endpoints.
We delve further into the endpoints story and created a complementary modulette titled, Statistical Methods Used with Survival Endpoints. To demystify technical, statistical terms commonly seen in oncology clinical trials, we define and include examples and explanations of Kaplan-Meier curves, hazard ratios, confidence intervals, and P values.
Other new modulettes provide detailed overviews on Integrated Delivery Networks and Health Economics Outcomes Research.
As we move into 2020, modulettes have been revised to reflect the current changes occurring in the oncology landscape. For example, in the Ways MCOs and PBMs Use to Contain Costs, we now include an explanation of direct and indirect remuneration (DIR) fees and the controversy associated with PBMs.
The Oncology Care Model now requires most of the participating practices to enter an "alternative 2-sided risk payment track", and MACRA has 2020 requirements practices need to meet to receive an adjusted payment.
Current State of Oncology Care highlights many of the areas in the oncology landscape undergoing changes, topics include, innovations in cancer treatments, emerging clinical trial designs and payment models, new reimbursement contracting, and increased use of targeted oncology treatments.
CMS Programs and Policies continues to provide information on the Medicaid drug rebate program and 340B, but also includes CMS's changes to site-neutral payments and its proposed Oncology Care First model.
Follow the Pill continues to focus on the pharmaceutical supply chain for oral oncology drugs, and Follow the Vial now includes a deeper explanation on the 2-quarter lag in the reimbursement rate for practices purchasing Medicare Part B drugs through buy and bill.